To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks

Back to Search
Print
Bookmark Trial

NCT00946114

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Warszawa, , 01-138, Poland
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pulmonary Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Subjects aged 18 and over who have any of the following conditions:

- Idiopathic pulmonary arterial hypertension.

- PAH associated with connective tissue disease (CTD).

- PAH with surgical repair, at least 5yrs previously, of atrial septal defect (ASD), ventricular septal defect (VSD) patent ductus arteriosis (PDA) or aorta-pulmonary window.

2. Subjects with a mean pulmonary artery pressure (mPAP) > 25mmHg and a pulmonary artery wedge pressure (PAWP) < 15mmHg at rest, assessed via right heart catheterization.

3. Subjects whose baseline 6-min walk test distance was > 100m and < 450m.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. PAH secondary to any etiology other than those specified in the inclusion criteria.


2. Subjects with congenital heart disease (other than those specified in the inclusion
criteria), PAH due to thrombo-embolism, HIV, chronic obstructive airways disease,
congestive heart failure.


3. Subjects whose 6-Minute Walk test might have been limited by conditions other than
PAH, associated dyspnea or fatigue.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Pulmonary HypertensionTo Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks NCT00946114
  1. Warszawa,
  2. Zabrze,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pulmonary HypertensionSildenafil IV Bolus Study NCT00800592
  1. Bruxelles,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pulmonary HypertensionA Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension NCT00644605
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. La Jolla, California
  5. La Jolla, California
  6. Los Angeles, California
  7. Los Angeles, California
  8. Los Angeles, California
  9. San Diego, California
  10. Torrance, California
  11. Torrance, California
  12. Aurora, Colorado
  13. Denver, Colorado
  14. Chicago, Illinois
  15. Shreveport, Louisiana
  16. Baltimore, Maryland
  17. Boston, Massachusetts
  18. Ann Arbor, Michigan
  19. Rochester, Minnesota
  20. New York, New York
  21. Durham, North Carolina
  22. Nashville, Tennessee
  23. Houston, Texas
  24. Milwaukee, Wisconsin
  25. Darlinghurst, New South Wales
  26. Melbourne, Victoria
  27. Bruxelles,
  28. Leuven,
  29. Sao Paulo, SP
  30. Prague 4,
  31. Prague 4,
  32. Kobenhavn,
  33. Clamart,
  34. Berlin,
  35. Giessen,
  36. Giessen,
  37. Hannover,
  38. Leipzig,
  39. Shatin N T,
  40. Budapest, Pest
  41. Zalaegerszeg, Zala
  42. Petach Tikva,
  43. Tel Hashomer,
  44. Bologna,
  45. Pisa,
  46. Pisa,
  47. Suwon,
  48. Kuala Lumpur,
  49. Tlalpan,
  50. Amsterdam,
  51. Oslo,
  52. Katowice,
  53. Warszawa,
  54. Warszawa,
  55. Zabrze,
  56. Singapore,
  57. Cape Town,
  58. Johannesburg,
  59. Parow,
  60. Barcelona,
  61. Barcelona,
  62. Madrid,
  63. Goteborg,
  64. Molndal,
  65. Papworth Everard, Cambridgeshire
  66. Sheffield, South Yorkshire
  67. Glasgow,
  68. High Heaton, Newcastle-upon-tyne,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Pulmonary HypertensionA Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension NCT00853112
  1. Phoenix, Arizona
  2. Phoenix, Arizona
  3. Phoenix, Arizona
  4. Gainesville, Florida
  5. Omaha, Nebraska
  6. Pittsburgh, Pennsylvania
  7. Dallas, Texas
  8. Dallas, Texas
  9. London, Ontario
  10. London, Ontario
  11. Montreal, Quebec
  12. Heidelberg,
  13. Hyderabad, Andhra Pardesh
  14. Tirupati, Andhra Pardesh
  15. Vadodara, Gujarat
  16. Mangalore, Karnataka
  17. Moscow,
  18. Moscow,
  19. Barcelona,
  20. Barcelona,
  21. Madrid,
  22. Lund,
  23. Umea,
  24. Uppsala,
  25. Zuerich,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks
Official Title A Local, Multi-Centre, Open Label Access Study, To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For One Hundred Twelve Weeks / Prior To Reimbursement And Availability For Patients In Poland.
Brief Summary The purpose of this study is to provide sildenafil therapy to eligible adult patients with pulmonary arterial hypertension (PAH) and to the patients who completed the A1481142 study for the treatment of PAH in Poland. Only safety and tolerability data will be collected in these patients.
Detailed Description Not Provided
Study Type Observational
Study Design Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Expanded access
Condition Pulmonary Hypertension
Intervention
  • Drug: sildenafil
    tablets, 20mg, TID, 112 weeks at the maximum
  • Drug: sildenafil
    tablets, 20mg x 4 (80mg), TID, approximately 70 weeks
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: March 29, 2010)		32
Original Enrollment Not Provided
Actual Study Completion Date March 2009
Actual Primary Completion Date March 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Subjects aged 18 and over who have any of the following conditions:

    • Idiopathic pulmonary arterial hypertension.
    • PAH associated with connective tissue disease (CTD).
    • PAH with surgical repair, at least 5yrs previously, of atrial septal defect (ASD), ventricular septal defect (VSD) patent ductus arteriosis (PDA) or aorta-pulmonary window.
  2. Subjects with a mean pulmonary artery pressure (mPAP) > 25mmHg and a pulmonary artery wedge pressure (PAWP) < 15mmHg at rest, assessed via right heart catheterization.
  3. Subjects whose baseline 6-min walk test distance was > 100m and < 450m.

Exclusion Criteria:

  1. PAH secondary to any etiology other than those specified in the inclusion criteria.
  2. Subjects with congenital heart disease (other than those specified in the inclusion criteria), PAH due to thrombo-embolism, HIV, chronic obstructive airways disease, congestive heart failure.
  3. Subjects whose 6-Minute Walk test might have been limited by conditions other than PAH, associated dyspnea or fatigue.
Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Poland
Removed Location Countries  
 
Administrative Information
NCT Number NCT00946114
Other Study ID Numbers A1481242
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2013